Office:	5150 Centre Avenue
	UPMC Cancer Pavilion 5th floor
	Pittsburgh, PA 15232
Phone:	412-692-4724
Fax:	412-648-6579
E-mail:	applemanlj@upmc.edu

Education
	A.B. Molecular Biology, Princeton University, 1988
	MD, New York University, 1995
	PhD Cell and Molecular Biology, New York University, 1995

Training
	Residency in Medicine, Beth Israel Hospital, Boston, 1998
	Fellowship-Hematology/Oncology, Dana-Farber/Partners CancerCare, 2000

Dr. Appleman’s current research efforts in the field of tumor immunology include collaboration with Dr. Pawel Kalinski, conducting clinical trial of an autologous dendritic cell vaccine in patients with biochemical recurrence of prostate cancer (UPCI 06-070). Dr. Appleman is also working with Dr. Michael Lotze on another investigator initiated phase I study of high dose interleukin-2 plus hydroxychloroquine (UPCI 11-080) and has co-authored a review on inhibiting autophagy in renal cell carcinoma with his collaborators (Lotze, Maranchie and Appleman 2013, Cancer J.). He is site principal investigator for the NCI-funded Cancer Immunotherapy Trials Network (CITN) study of interleukin-7 and sipuleucel-T for men with castration-refractory prostate cancer and was the site P.I. for the Cytokine Working Group IL-2 Select study (McDermott et al. 2014, Clin. Cancer Res.). He also serves as site P.I. for several industry-sponsored studies that are investigating cancer immunotherapy. One of these studies was presented at ASCO in 2014 (Choueiri et al.).

In the areas of signal transduction and targeted therapy, Dr. Appleman is the national chair of ECOG 2810-Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy. This NCI/CTEP-sponsored study is open throughout the ECOG, SWOG and ALLIANCE cooperative groups. Dr. Appleman was the University of Pittsburgh site P.I. for a phase I study of the angiopoeitin antagonist peptibody AMG-386 (trebananib) (Hong et al. 2014 Clin. Genitourin. Cancer (senior author)). He is site P.I. for a completed phase I study of the phosphoinositol-3 kinase inhibitor, BAY 80-6946 (presented ASCO 2011 with manuscript in preparation) and of a phase II study of the vascular endothelial growth factor inhibitor linifanib (ABT-869) Tannir et al. 2011 Eur. J. Cancer). Dr. Appleman was the University of Pittsburgh site Principal Investigator for the registration studies that led to the FDA approval of abiraterone and enzalutamide in metastatic prostate cancer.

Dr. Appleman is also conducting research investigator-initiated research into novel cytotoxic treatment strategies. He is collaborating with Dr. Susan Bates at the NCI on a translational study of the bicunctional alkylating agent, DMS612 in patients with solid tumors (Appleman et al. Clin. Cancer Res. 2015). Dr. Appleman is the coordinating center principal investigator of a phase I study of the PARP inhibitor ABT-888 plus carboplatin and paclitaxel in patients with solid tumors (presented ASCO 2012 and manuscript in preparation). Dr. Appleman was the University of Pittsburgh site principal investigator of a practice-changing phase 2 study of neoadjuvant dose dense MVAC (methotrexate, vinblastine, Adriamycin and cisplatin) in patients with muscle-invasive bladder cancer) (Choueiri et al. 2014 J. Clin. Oncol.)

For my complete bibliography, Click Here.

Selected Publications: